ClinicalTrials.gg
CompletedNCT00234975Updated Jan 3, 2013

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

A Phase 4 interventional study of Lopinavir/Ritonavir in HIV Infection, sponsored by AbbVie (prior sponsor, Abbott). Completed at 11 sites in Puerto Rico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-01-03.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 331 studies in HIV Infections with a site in Puerto Rico — 1 open to participants now, 8 under way, 3 of them phase 3. HIV Infections · Puerto Rico.

Enrollment
188th of 273
86 · median 200
Started
2002
with 11 others
Phase 4
18 of 331
none open now
Registered
219th of 331
by date

Among the 331 studies in HIV Infections with a site in Puerto Rico, this one is the 188th largest by enrollment of the 273 interventional ones that give a count, is one of 12 that started in 2002, is one of 18 in phase 4, and was the 219th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 331 studies in HIV Infections with a site in Puerto Rico is open now. Recruiting first, the newest first:

A study can be open while its sites in Puerto Rico have not opened yet or have stopped. Only those recruiting at a site in Puerto Rico →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 331 studies in HIV Infections with a site in Puerto Rico, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.

03

Conditions studied

  • HIV Infection

Browse trials for

Keywords

  • Lopinavir
  • Ritonavir
  • Phase 4
  • HIV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented positive.
  • At least 18 years of age.
  • Does not exhibit evidence of acute illness (especially any acute liver disease, except )
  • Subject has not been treated for an active opportunistic infection within 30 days of the baseline visit.
  • Subject Has a Score greater than or equal to 70.
  • Subject does not require and agrees not to take, for the duration of the study, any of the following medications that are with Kaletra: astemizole, terfenadine, midazolam, triazolam, cisapride, certain ergot derivatives (ergotamine, dihydroergotamine, ergonovine, and methylergonovine), pimozide, propafenone and flecainide. Rifampin, a potent enzyme inducer, should not be administered with the study medication, because of the possibility of significant decreases in Kaletra concentration during concurrent administration.
  • The subject agrees not to take any medication, including over-the-counter medicine, alcohol, recreational drugs or herbal preparations without the knowledge and permission of the principal investigator.
  • Subject had laboratory testing within the previous three months and the most recent testing demonstrates all of the following: > 8.0 g/dL; > 750 cells/mL; count > 20,000/mL; or AST \</=10 x (ULN); Creatinine\< 1.5 x ULN; Triglycerides \</=750 mg/dL.
  • Subjects have no evidence of grade III or IV adverse event or laboratory abnormality (except for LFTs).

Exclusion criteria

Exclusion Criteria:

No exclusion criteria.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Active comparator
    HCV +

    Drug: Lopinavir/Ritonavir

  • Active comparator
    HCV -

    Drug: Lopinavir/Ritonavir

Interventions

  • DrugLopinavir/Ritonavir

    400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator

    Also known as: ABT-378, lopinavir/ritonavir, Kaletra

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure

    Changes in liver functions enzyme.

    Time frame: Baseline, Week 4, Week 8, Week 16 and Week 24

Secondary outcomes

  1. Secondary Outcome Measures

    Changes in HIV viral load, CD4/CD8 cell count, and Hepatitis C viral load

    Time frame: Baseline, Week 4, Week 8, Week 16 and Week 24

07

Study locations

11 sites
  • Site Reference ID/Investigator# 4118
    Bayamon, 00960, Puerto Rico
  • Site Reference ID/Investigator# 4119
    Bayamon, 00961, Puerto Rico
  • Site Reference ID/Investigator# 6298
    Juana Diaz, 00795, Puerto Rico
  • Site Reference ID/Investigator# 6284
    Las Piedras, 00771, Puerto Rico
  • Site Reference ID/Investigator# 4101
    Mayaguez, 00680, Puerto Rico
  • Site Reference ID/Investigator# 4116
    Playa de Ponce, 00731, Puerto Rico
  • Site Reference ID/Investigator# 4117
    Ponce, 00717-1563, Puerto Rico
  • Site Reference ID/Investigator# 4099
    Ponce, 00731, Puerto Rico
  • Site Reference ID/Investigator# 4086
    Rio Piedras, 00926, Puerto Rico
  • Site Reference ID/Investigator# 4080
    San Juan, 00908, Puerto Rico
  • Site Reference ID/Investigator# 4100
    Santurce, 00909, Puerto Rico
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Oct 10, 2005
Start
Oct 2002
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Last update
Jan 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00234975
Responsible party
Sponsor
First posted
Oct 10, 2005
Start date
Oct 2002
Primary completion
Jan 2008
Completion
Jan 2008
Last update
Jan 3, 2013

Study contacts

Carlos R Rivera-Vazquez, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion